LAUSR: cmet amplification

Photo by myriamzilles from unsplash

Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.

Sign Up to like & get
recommendations!
0 Published in 2018 at "Lung cancer"

DOI: 10.1016/j.lungcan.2018.07.030

Abstract: PURPOSE Next to secondary epidermal growth factor receptor (EGFR) mutations, cMET amplification plays an important role in mediating acquired resistance to EGFR tyrosine kinase inhibitors (TKI) treatment. Crizotinib, a dual ALK and cMET inhibitor, can… read more here.

Keywords: treatment; cmet amplification; egfr tki; amplification ... See more keywords

LAUSR

You are not signed in:

Sign Up!

Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.